Volume 25, Number 11—November 2019
Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019
|Influenza virus||Median IC50 + SD, nmol/L
|Baloxavir||NA inhibitors (WHO criteria)
|A/Kanagawa/IC18141/2019||236.08||0.37 (NI)||0.18 (NI)||1.01 (NI)||1.27 (NI)|
|A(H3N2) of 2018–19||1.27 + 1.08†||0.37 + 0.17‡||0.13 + 0.03‡||0.79 + 0.33‡||1.00 + 0.21‡|
*We determined antiviral susceptibilities using a focus reduction assay and a fluorescent NA inhibition assay (NA-Fluor Influenza Neuraminidase Assay Kit; Applied Biosystems, https://www.thermofisher.com) (4) and calculated IC50 values using MikroWin 2010 (Labsis, https://labsis.de). We expressed NA inhibitor susceptibilities using WHO criteria for influenza A virus inhibition, which define susceptibility on the basis of the -fold change in IC50 compared with the IC50 of reference isolates (6). WHO inhibition was defined as normal (<10-fold increase), reduced (10–100-fold increase), or highly reduced (>100-fold increase) in comparison with the median value of isolates from the same influenza season. IC50, 50% inhibitory concentration; NA, neuraminidase; NI, normal inhibition; WHO, World Health Organization.
†n = 83.
‡n = 170.
- Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al.; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913–23. DOIPubMedGoogle Scholar
- Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8:9633. DOIPubMedGoogle Scholar
- Shionogi & Co. Ltd. Research and development at Shionogi. 2019 Mar 14 [cited 2019 May 27]. http://www.shionogi.co.jp/en/ir/pdf/e_p190314.pdf
- Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, et al. Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Front Microbiol. 2018;9:3026. DOIPubMedGoogle Scholar
- Takashita E, Kawakami C, Ogawa R, Morita H, Fujisaki S, Shirakura M, et al. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Euro Surveill. 2019;24. DOIPubMedGoogle Scholar
- World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012;87:369–74.PubMedGoogle Scholar
- Takashita E, Kawakami C, Morita H, Ogawa R, Fujisaki S, Shirakura M, et al.; On Behalf Of The Influenza Virus Surveillance Group Of Japan. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill. 2019;24. DOIPubMedGoogle Scholar
- Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759–65. DOIPubMedGoogle Scholar
- Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127–33. DOIPubMedGoogle Scholar
- Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DAT. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9:291–300. DOIPubMedGoogle Scholar
- Lau LL, Cowling BJ, Fang VJ, Chan KH, Lau EH, Lipsitch M, et al. Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis. 2010;201:1509–16. DOIPubMedGoogle Scholar